Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Prolactin may contribute to hair loss, but targeting its receptor won't cure androgenetic alopecia. ABS-201 could be a useful alternative or adjuvant therapy, similar to JAK inhibitors, but not more effective than HMI-115.

Taking 5mg oral minoxidil at night instead of splitting 2.5mg doses, with the rationale that a single larger dose may provide a stronger activation for hair follicles and reduce peak-related side effects. Some users report sleep issues with nighttime dosing, while others find it beneficial; opinions on effectiveness and side effects vary.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

Oral minoxidil can cause rare facial bloating, especially at higher doses and in women. Reducing sodium intake, drinking more water, and adjusting the dose can help manage side effects.

A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.

DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.

The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

Deoxyribose sugar gel may stimulate hair regrowth similarly to minoxidil by enhancing blood supply and follicle activity. Human trials are necessary, and current products have mixed results.

A user experienced hair thinning after inconsistent use of finasteride and minoxidil while living abroad. They are now considering switching to dutasteride, which some believe is more effective, though others caution it may not work better for everyone.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

Finasteride, dutasteride, and minoxidil are discussed as treatments for male pattern baldness. Finasteride and dutasteride are effective DHT blockers, while minoxidil is necessary for regrowth but must be used consistently.

A new light therapy claims to reduce hair loss markers by 92% using a specific wavelength range. Users discuss the cost and effectiveness of devices, with some expressing skepticism and others considering alternative treatments like red light therapy and vitamin D exposure.

Using dutasteride anally as a hair loss treatment, with humorous and satirical comments on its effects and implications.

An 18-year-old started taking finasteride for early-stage hair loss, prescribed by a dermatologist who advised against waiting due to potential follicle loss. The conversation includes differing opinions on starting finasteride early, with some users sharing personal experiences and concerns about potential side effects.

Using both finasteride and dutasteride for hair loss is debated, with some seeing it as beneficial during transition, while others find it redundant and risky. Oral minoxidil raises concerns about blood pressure, with a preference for topical use and microneedling for better results.

A 31-year-old is happy with hair regrowth and thickening after using 0.5 mg dutasteride daily and 5% topical minoxidil. Initial results appeared in six months, with continued improvement over time.

New hair loss treatments like GT20029 and PP405 could potentially replace minoxidil and finasteride, offering better results with fewer side effects. However, current treatments like finasteride and minoxidil are still effective for many, despite concerns about side effects.

Ketoconazole can slightly improve hair density and is best used as an adjunct to treatments like finasteride and minoxidil. It helps with scalp health but won't stop androgenetic alopecia on its own.

Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.

Creatine is believed by some to cause hair loss, potentially by increasing DHT levels, despite conflicting evidence. Users report mixed results when combining creatine with treatments like finasteride, dutasteride, and minoxidil.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The user experienced worsening hair loss despite using finasteride and topical minoxidil for two years and is considering oral minoxidil and dutasteride. Suggestions include microneedling, stress management, and alternative treatments like topical finasteride or ketoconazole shampoo.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.

Minoxidil is often applied once or twice daily for hair growth, but many find it inconvenient and switch to once daily or oral minoxidil for ease. Some users combine it with finasteride for better results, despite potential side effects.

The user tried a product labeled as PP405 from Umbrella Labs for hair loss but saw no changes, and it was revealed to be a fake or misidentified product. The user is also using finasteride, minoxidil, and other treatments but is still experiencing hairline issues.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

The user is considering switching from finasteride and oral minoxidil to dutasteride and a higher dose of oral minoxidil, taken intermittently, based on their dermatologist's advice. They are unsure about claims that finasteride loses effectiveness after a year and that minoxidil doesn't need daily dosing, and they are seeking community input on these points.

A new alcohol-free, propylene glycol-free topical finasteride foam is available for prescription in Canada and the USA, offering a cleaner alternative for hair loss treatment. The product also offers a combination of 0.1% finasteride with 5% minoxidil and aims to be affordable and less irritating for sensitive scalps.

Creatine may cause hair loss in some individuals, especially those on finasteride, despite no scientific link. Personal experiences suggest individual sensitivity to DHT could be a factor.